Back

Clinical Trial Monitoring

08-07-2015
Clinical Trial MonitoringClinical Trial Monitoring
Clinical Trial MonitoringClinical Trial Monitoring
Monitoring is key when carrying out any clinical trial. At BioClever,  all clinical trials are monitored using state-of-the-art tools, which facilitate follow-up and allow investigators to associate data from different studies, under the control of the Project Manager, our link with the client, always ready for clarifying any doubts about the design or development of the studies or trials conducted. 
  
Thus, clinical trial monitoring helps control (and sometimes predict), at any time, any issues that may require more time; or, if it involves an unexpected circumstance, it enables us to offer a quick solution to prevent any modifications of the results of the clinical trial that is being conducted and thus allow us to conclude it with the utmost reliability and professionalism that characterize us.

Monitoring our clinical trials to obtain results

At BioClever we have a specific tool to monitor clinical trials that allows anyone involved, whether the investigator, the client or the Project Manager, to control the different phases. This system is Clinsight, an electronic tool that allows us to carry out and automate the whole clinical trial process, thus enabling us to monitor it in a faster, more agile and reliable way, with access to any information that may be required at any time to finish preparing the final report.  

Share

Related news

Phases of a Clinical Trial
04-03-2020

Phases of a Clinical Trial

A clinical trial cannot be started until it has been approved by the competent agencies designated by law. In Spain, approvals are granted by the  Spanish Agency of Medicinal Products and Medical Devices (AEMPS) and an accredited Medical Research and Ethics Committee (MREC). 
The key role of Contract Research Organizations
13-01-2016

The key role of Contract Research Organizations

Research has always required a substantial investment in time and money but, since the onset of the crisis, R&D has been badly hit across all industries, and the pharmaceutical sector is no exception.